VALIDATION OF A PREDICTIVE SCORE OF ACUTE CHEST SYNDROME (PRESEV-2)

• Research type

  Research Study

• Full title

  VALIDATION OF A PREDICTIVE SCORE OF ACUTE CHEST SYNDROME (PRESEV-2 STUDY)

• IRAS ID

  173039

• Contact name

  Pablo Bartolucci

• Contact email

  pablo.bartolucci@hmn.aphp.fr

• Sponsor organisation

  SAMG, unité des maladies génétiques du globule rouge at Henri Mondor Hospital.

• Duration of Study in the UK

  1 years, 11 months, 31 days

• Research summary

  Vaso-Occlusive Crisis (VOC), the most common manifestation of sickle cell disease (SCD), is the first cause of death, particularly when complicated by an acute chest syndrome (ACS).
  In the PRESEV study I, we developed a predictive score of secondary ACS in SCD patient admitted in the hospital for VOC. 250 patients with severe VOC requiring hospitalization were included, from whom 19% developed a secondary ACS at the third day of the hospitalization. Biological and clinical data were collected. A multivariate analysis of these data established a predictive score (AUC = 0.840 [95% CI: 0.780 – 0.900]) of secondary ACS on admission, with a negative predictive value of 98.8% for the low level risk and a positive predictive value of 39.5%. The PRESEV score could help the physicians to better manage VOC and could be used for future therapeutic trials. This predictive score of secondary ACS has to be validated in a multicenter international study.

• REC name

  London - City & East Research Ethics Committee

• REC reference

  16/LO/2084

• Date of REC Opinion

  7 Apr 2017

• REC opinion

  Further Information Favourable Opinion